EUVIMEDEUVIMED entdecken
Systematische ÜbersichtMetaanalyseOpen Access · CC BY-NC 4.0

Clinical outcomes of continuing vs. discontinuing oral anticoagulation after atrial fibrillation ablation: an updated systematic review and meta-analysis of observational studies and randomized controlled trials

Sandeep Samethadka Nayak, Ehsan Amini-Salehi iD, Negin Letafatkar iD, Arash Arya iD, Shahriar Ghodous iD, Maryam Jafari iD, Amir Nasrollahizadeh iD, Anoop Gurram iD, Javad Nadali iD, Seyedeh Mohadese Mosavi Mirkalaie iD, Anya Patel iD, Payam Kabiri iD und 3 weitere

Europace · 03.07.2026 · 28 (7)

DOI: 10.1093/europace/euag104 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Europace, online erschienen am 08.07.2026. Verfasst von Sandeep Samethadka Nayak und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Yale New Heaven Health Bridgeport Hospital, 267 Grant St, Bridgeport, CT, USA. Hauptthemen laut MEDLINE: Atrial Fibrillation, Anticoagulants, Catheter Ablation, Stroke. Die Arbeit nennt 58 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

Continuation of oral anticoagulation (OAC) after successful atrial fibrillation (AF) ablation remains debated. With recent randomized controlled trials addressing this question, an updated meta-analysis is needed to inform clinical decision-making. Methods and results A comprehensive search of PubMed/MEDLINE, Embase, Web of Science, and Scopus was performed through 24 November 2025, to identify studies comparing clinical outcomes in patients who continued vs. discontinued OAC after AF catheter ablation. Overall, continuing OAC was not significantly associated with the risk of stroke/TIA (OR: 1.48, 95% CI: 0.84–2.60; P = 0.16). However, when stratified by CHA2DS2-VASc score, patients with scores ≥2 had a significantly lower risk of stroke/TIA with OAC continuation (OR: 0.42, 95% CI: 0.18–0.95; P = 0.04). This protective effect was further supported in studies with well-balanced baseline risk between groups, where OAC continuation was associated with a significantly lower risk of stroke/TIA (OR: 0.50, 95% CI: 0.34–0.72; P < 0.01). Conversely, OAC continuation significantly increased the risk of major bleeding. No significant association was observed for major adverse cardiac events or all-cause mortality.

Conclusion

In patients with CHA2DS2-VASc scores ≥2, particularly when baseline risk is well-balanced between groups, continuation of OAC after AF ablation is associated with a significantly lower risk of stroke/TIA. These findings support continuing OAC in higher-risk patients (CHA2DS2-VASc ≥2). However, given the significantly increased risk of major bleeding associated with OAC continuation, the decision to continue anticoagulation in lower-risk patients requires careful consideration, as no clear thromboembolic benefit was observed in this population.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Atrial FibrillationAnticoagulantsCatheter AblationStrokeIschemic Attack, TransientHumansAdministration, OralRandomized Controlled Trials as TopicObservational Studies as TopicTreatment OutcomeRisk FactorsTreatment InterruptionRisk Assessment

Stichwörter der Autor:innen

Atrial fibrillationCatheter ablationMajor bleedingOral anticoagulationStroke

Substanzen

Anticoagulants

Autor:innen und Institutionen

  • Department of Internal Medicine, Yale New Heaven Health Bridgeport Hospital, 267 Grant St, Bridgeport, CT, USA.
  • School of Medicine, Guilan University of Medical Sciences, Rasht, Iran.
  • Department of Internal Medicine III, Halle University Hospital, Halle (Saale), Germany.
  • Tehran Heart Center, Cardiovascular Diseases Research Institute, Tehran University of Medical Sciences, Tehran, Iran.
  • Department of Hospital Medicine, Cleveland Clinic, Cleveland, OH, USA.
  • Nursing Research Center, Golestan University of Medical Sciences, Gorgan, Iran.

ORCID-Profile: Ehsan Amini-Salehi, Negin Letafatkar, Arash Arya, Shahriar Ghodous, Maryam Jafari, Amir Nasrollahizadeh, Anoop Gurram, Javad Nadali, Seyedeh Mohadese Mosavi Mirkalaie, Anya Patel, Payam Kabiri, Darshan Madhav Sonde, Bita Amirian, Ali Bozorgi

Zitieren

APA

Nayak, S. S., Amini-Salehi, E., Letafatkar, N., Arya, A., Ghodous, S., Jafari, M., Nasrollahizadeh, A., Gurram, A., Nadali, J., Mosavi Mirkalaie, S. M., Patel, A., Kabiri, P., Sonde, D. M., Amirian, B., & Bozorgi, A. (2026). Clinical outcomes of continuing vs. discontinuing oral anticoagulation after atrial fibrillation ablation: an updated systematic review and meta-analysis of observational studies and randomized controlled trials. Europace, 28(7). https://doi.org/10.1093/europace/euag104

Vancouver

Nayak SS, Amini-Salehi E, Letafatkar N, Arya A, Ghodous S, Jafari M, et al. Clinical outcomes of continuing vs. discontinuing oral anticoagulation after atrial fibrillation ablation: an updated systematic review and meta-analysis of observational studies and randomized controlled trials. Europace. 2026;28(7). doi:10.1093/europace/euag104

BibTeX
@article{Nayak2026,
  author = {Nayak, Sandeep Samethadka and Amini-Salehi, Ehsan and Letafatkar, Negin and Arya, Arash and Ghodous, Shahriar and Jafari, Maryam and Nasrollahizadeh, Amir and Gurram, Anoop and Nadali, Javad and Mosavi Mirkalaie, Seyedeh Mohadese and Patel, Anya and Kabiri, Payam and Sonde, Darshan Madhav and Amirian, Bita and Bozorgi, Ali},
  title = {Clinical outcomes of continuing vs. discontinuing oral anticoagulation after atrial fibrillation ablation: an updated systematic review and meta-analysis of observational studies and randomized controlled trials},
  journal = {Europace},
  year = {2026},
  volume = {28},
  number = {7},
  doi = {10.1093/europace/euag104}
}
Kostenlos starten →